Hyundai Bioscience Confirms Potential to Overcome 'False Resistance' in Phase 1 Prostate Cancer Trial
- Input
- 2026-11-19 15:43:07
- Updated
- 2026-11-19 15:43:07

Hyundai Bioscience announced on the 18th that it had disclosed observational results from an ongoing Phase 1 trial for metastatic castration-resistant prostate cancer at Seoul National University Hospital in a shareholder notice. On the 19th, it said the results confirmed the potential to overcome “false resistance” in actual patients.
According to the company, about 20 million people develop cancer worldwide each year and about 10 million die; of these, about 90% die from metastatic rather than primary cancer. The company cited resistance to anticancer drugs as the reason.
The company describes false resistance as follows: When anticancer drugs are administered repeatedly, the tissue surrounding cancer cells hardens before the cancer cells develop genetic mutations. This tissue acts like a defensive barrier, blocking drug penetration so the anticancer drug cannot reach the cancer cells at a concentration high enough to kill them. In other words, the drug is not failing to work; it is failing to reach the cancer cells. Penitrium does not attack the cancer cells directly. Instead, it normalizes only this barrier, allowing existing anticancer drugs to reach them again.
In the trial, blood levels of prostate-specific antigen (PSA) fell in both patients with resistance to one of the two standard prostate cancer drugs. The first patient, who had developed resistance to abiraterone, saw PSA levels fall repeatedly after receiving enzalutamide with Penitrium (600 mg per day); the size of metastatic lesions also decreased on CT scans. There were no adverse reactions during the 12 weeks of treatment, and approval was obtained from the Ministry of Food and Drug Safety for about six months' worth of individual treatment use.
The second patient’s PSA had continued to rise for 10 months after treatment was stopped because of resistance to enzalutamide. When the previously unsuccessful enzalutamide was used again with Penitrium, PSA fell in both the first and second weeks of treatment. The company said the administered dose was about one-thirty-fourth of the maximum no-observed-adverse-effect level (NOAEL) in animal studies.
However, these results are based on observations of two patients in an ongoing Phase 1 trial. Further trials involving more patients are needed to confirm efficacy and safety.
CEO Jin Geun-woo said, “We confirmed in actual patients that the drug they had been taking worked again without having to switch to a stronger anticancer drug.”
[email protected] Jung Sang-hee Reporter